The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2015

Filed:

Mar. 18, 2011
Applicants:

Kumaresh Soppimath, Monmouth, NJ (US);

Satish Pejaver, Bridgewater, NJ (US);

Kanaiyalal R. Patel, Union, NJ (US);

Lakkaraju Dasaradhi, Princeton Junction, NJ (US);

Rama Sodum, Princeton, NJ (US);

Hari Desu, Plainsboro, NJ (US);

Navneet Puri, Bridgewater, NJ (US);

Inventors:

Kumaresh Soppimath, Monmouth, NJ (US);

Satish Pejaver, Bridgewater, NJ (US);

Kanaiyalal R. Patel, Union, NJ (US);

Lakkaraju Dasaradhi, Princeton Junction, NJ (US);

Rama Sodum, Princeton, NJ (US);

Hari Desu, Plainsboro, NJ (US);

Navneet Puri, Bridgewater, NJ (US);

Assignee:

Innopharma, Inc., Piscataway, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/69 (2006.01); A61K 31/4965 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/10 (2006.01); A61K 9/19 (2006.01);
U.S. Cl.
CPC ...
A61K 31/69 (2013.01); A61K 31/4965 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 47/10 (2013.01);
Abstract

Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.


Find Patent Forward Citations

Loading…